In the first half of the year, Chinese biotech firms saw a shift in their financial landscape, with cross-border licensing deals becoming the primary driver of profitability. For many companies that were previously operating at a loss, these partnerships with multinational drugmakers provided a vital lifeline, effectively replacing initial public offerings (IPOs) and traditional pre-IPO fundraising as the main source of capital. This funding is essential for these firms to continue their research, clinical trials, and the regulatory approval process for new drug candidates.

Despite this recent success, the outlook for the remainder of the year is becoming more uncertain. Multinational pharmaceutical companies are beginning to signal a tightening of their deal-making budgets. As these global giants adopt a more cautious stance, the reliance of Chinese biotech firms on these external partnerships may leave them vulnerable. While the industry has successfully used these deals to bridge funding gaps, the potential reduction in global investment suggests that the rapid growth seen in the first half of the year may be difficult to sustain if international partners scale back their commitments.